Fig. 1. Proportion constituting the hepatocellular carcinoma treatment costs. RFA, radiofrequency ablation; TACE, transarterial chemoembolization

Korean J Clin Pharm 2021;31:153-9 https://doi.org/10.24304/kjcp.2021.31.2.153

© 2021 Korean J Clin Pharm